PMCB 8-K: Material agreement

Filed with the SEC on · accession 0001683168-26-008964

PMCB filed a 8-K (current report) with the SEC on Nov 19, 2026. PharmaCyte Biotech exchanged 851,304 Series G warrants to purchase Q/C Technologies common stock for 4,982,272 shares of Q/C common stock, and consented to extend the maturity of Q/C's Series H Preferred Stock from March 2027 to September 2027. The stock moved -10.6% by the first close after the filing.

Summary of the filing

PharmaCyte Biotech exchanged 851,304 Series G warrants to purchase Q/C Technologies common stock for 4,982,272 shares of Q/C common stock, and consented to extend the maturity of Q/C's Series H Preferred Stock from March 2027 to September 2027. The CEO of PharmaCyte also serves as CEO of Q/C, making this a related-party transaction.

Key details

Number of Series G Long-Term Warrants exchanged$851K
Number of Q/C common shares received in exchange$5.0M
Reference price per Q/C common share used to determine exchange ratio$0
Registrant; holder of q/c warrants and preferred stock; exchanged warrants for q/c common sharesPharmaCyte Biotech, Inc.
Counterparty; issued exchange shares and agreed to extend series h preferred stock maturityQ/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.)
Chief executive officer and chairman of the board of pharmacyte biotech; chief executive officer of q/c technologiesJoshua N. Silverman

How PMCB stock reacted

Close before

$5.37

Nov 18, 2026

First close after

-10.61%

$4.80

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for PMCB, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PMCB?

Click here

Frequently asked questions

What did PMCB file with the SEC on Nov 19, 2026?

PMCB filed a 8-K (Material agreement). PharmaCyte Biotech exchanged 851,304 Series G warrants to purchase Q/C Technologies common stock for 4,982,272 shares of Q/C common stock, and consented to extend the maturity of Q/C's Series H Preferred Stock from March 2027 to September 2027. The CEO of PharmaCyte also serves as CEO of Q/C, making this a related-party transaction.

What does a material agreement mean for PMCB stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did PMCB stock react to this filing?

PMCB closed at $5.37 before the filing and $4.80 on Nov 19, 2026 (-10.61%).

Other PMCB SEC filings

Get alerts when PMCB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days